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Abstract:  Our  preliminary  screening  has  shown  that  curcumin  derivative  BDMC33  
[2,6-bis(2,5-dimethoxybenzylidene)cyclohexanone] exerted promising nitric oxide inhibitory 
activity in activated macrophages. However, the molecular basis and mechanism for its 
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pharmacological action is yet to be elucidated. The aim of this study was to investigate the 
anti-inflammatory properties of BDMC33 and elucidate its underlying mechanism action in 
macrophage cells. Our current study demonstrated that BDMC33 inhibits the secretion of 
major pro-inflammatory mediators in stimulated macrophages, and includes NO, TNF-α 
and  IL-1β  through  interference  in  both  nuclear  factor  kappaB  (NF-κB)  and  mitogen 
activator protein kinase (MAPK) signaling cascade in IFN-γ/LPS-stimulated macrophages. 
Moreover,  BDMC33  also  interrupted  LPS  signaling  through  inhibiting  the  surface 
expression of CD-14 accessory molecules. In addition, the inhibitory action of BDMC33 
not only restricted the macrophages cell (RAW264.7), but also inhibited the secretion of 
NO and TNF-α in IFN-γ/LPS-challenged microglial cells (BV-2). The experimental data 
suggests  the  inflammatory  action  of  BDMC33  on  activated  macrophage-like  cellular 
systems, which could be used as a future therapeutic agent in the management of chronic 
inflammatory diseases.  
Keywords: anti-inflammatory; BV-2; curcumin; MAPK; NF-κB; RAW 264.7 
 
1. Introduction 
Inflammation  is  a  beneficial  host  immune  response  to  tissue  injury  or  infection.  However, 
prolonged  or  uncontrolled  inflammation  may  lead  to  potentially  damaging  consequences  and 
contribute to pathogenesis of several inflammatory disorders and cancers [1]. Macrophages play a key 
role in inflammatory response and serve as a decisive interface in bridging both innate and adaptive 
immunity [2,3]. Lipopolysaccharide (LPS) and interferon-γ (IFN-γ) are an excellent combination of 
stimulus to act synergistically in macrophage activation [4,5]. LPS binds to TLR-4, facilitated by the 
CD-14 co-receptor, whereas IFN-γ prime the macrophages for more a rapid and heightened response to 
LPS [6,7]. TLR-4 stimulation, mediated by  LPS, recruits the cytoplasmic adaptor protein MyD88, 
subsequently  activating  two  distinct  downstream  signaling  pathways,  the  nuclear  factor  kappaB  
(NF-κB) pathway and the mitogen activated protein kinase (MAPK) pathway. These signaling pathways 
are known to stimulate the release of numerous inflammatory mediators such as nitric oxide (NO), 
cytokines, prostaglandin E2 and other eicosanoid mediators to promote inflammatory response [8]. 
Nitric oxide is a free radical generated by nitric oxide synthase (NOS) and serves as an important 
mediator in regulating the physiological and pathophysiological mechanism of cardiovascular, nervous 
and immunological systems. The expression of inducible NOS (iNOS) is responsible for the prolonged 
production of NO that mediates the bactericidal and tumoricidal functions of activated macrophages [9]. 
However,  excessive  production  of  NO  in  chronic  inflammation  has  been  implicated  in  the 
development  of  autoimmune  disorders  and  cancer  [10].  Besides,  a  number  of  pro-inflammatory 
cytokines  are  released  by  macrophages  during  inflammation,  including  tumor  necrosis  factor-α  
(TNF-α),  interleukin-1β  (IL-1β)  and  IL-6  [11].  These  cytokines  play  a  significant  role  in  the 
pathogenesis  of  various  inflammatory  diseases  and  serve  as  potent  biomarkers  to  assess  the 
inflammatory  process  [12].  As  a  result,  a  number  of  strategies  have  been  designed  to  block  the Int. J. Mol. Sci. 2012, 13                       
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expression of these pro-inflammatory mediators to enhance disease management, including the use of a 
specific inhibitor or the antagonizing effect of antibodies. 
NF-κB signaling plays a vital role in regulating cellular proliferation, inflammatory response and 
cell adhesion [13]. The activation of NF-κB has been reported to induce transcription of multiple  
pro-inflammatory cytokines and pivotal enzymes that are involved in maintaining inflammation such 
as iNOS, COX-2, TNF-α, IL-1β, IL-6 and others [14]. Generally, functionally active NF-κB consisting 
of Rel family p50 and p65 subunits are normally confined to an inactive cytoplasmic complex through 
binding to an inhibitory protein (I-κB) in unstimulated conditions. The activation of NF-κB causes 
rapid phosphorylation of I-κB at two critical serine residues (Ser
32 and Ser
36) by I-κB kinase (IKK) and 
the phosphorylated I-κB are targeted for ubiquitination and followed by 26s proteosomal degradation. 
The dissociation of I-κB enables the free NF-κB to translocate into the nucleus via specific machinery 
and bind to the κB binding sites in the promoter of the targets genes [15–17]. On the other hand, 
MAPK is one of the signal transduction cascades involved in the regulation of inflammatory mediator 
expression in activated macrophages. The MAPK family consists of three main sub-family members, 
including  extracellular signal-regulated kinase (ERK), p38 MAPK,  and c-Jun NH2-terminal kinase 
(JNK)  [18,19].  Persistent  activation  of  MAPK  signaling  pathways  has  been  implicated  in  the 
development of many human diseases, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic 
lateral  sclerosis  and  various  types  of  cancers  [20].  Therefore,  both  NF-κB  and  MAPK  signaling 
pathways  serve  as  important  molecular  targets  for  the  development  of  potential  anti-inflammatory 
drugs and present a promising chemotherapeutic strategy to control inflammatory disease. 
Curcumin  or  [1,7-bis-(hydroxy-3-methoxyphenyl)-1,6-heptadiena-3,5-dione]  is  a  yellow  pigment 
and naturally occurring phytochemical found in the rhizome of Curcuma longa L. (commonly known 
as turmeric) (Figure 1a). Within the last decade, the therapeutic and chemoprevention properties of 
curcumin  have  been  extensively  studied  because  of  its  wide  spectrum  of  pharmacological  
activity,  such  as  antioxidant,  anti-proliferative,  anti-carcinogenic,  anti-angiogenic,  anti-bacterial,  
immune-modulatory, and anti-inflammatory [21]. Pre-clinical studies have shown that curcumin is a 
highly pleiotophic molecule with immunomodulatory effects on different cellular models in preventing 
various inflammatory disorders, such as rheumatoid arthritis, neurodegeneration, inflammatory bowel 
disease and cardiovascular disease [22]. Curcumin has appeared to be a promising chemopreventive 
compound, which was proved to be safe and effective in many clinical trials. However, its clinical 
advancement has been hampered due to its poor pharmacokinetic properties [23]. It was believed that 
the instability of the curcumin structure was contributed to by its active methylene group and the  
β-diketone  moiety,  which  renders  curcumin  to  be  easily  degraded  by  aldo-keto  reductase  in  the  
liver [24]. Our group has adopted the chemical synthesis of a curcumin analogue by eliminating the 
unstable methylene group and β-diketone moiety, to overcome the limitation on its bioavailability. We 
previously have reported that BDMC33 [2,6-bis(2,5-dimethoxybenzylidene) cyclohexanone] exhibited 
improved  anti-inflammatory  activities  by  inhibiting  NO  production  in  the  IFN-γ/LPS-challenged 
macrophages  cell  (RAW  264.7)  [25].  However,  the  cellular  and  molecular  mechanism  underlying 
BDMC33-mediated inhibition of NO production in macrophages has yet to be elucidated. The present 
study  provides  evidence  that  BDMC33  exhibited  its  anti-inflammatory  activity  via  suppression  of  
NF-κB activation and AP-1 activities by blockade of ERK/JNK signaling pathways. Int. J. Mol. Sci. 2012, 13                       
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Figure 1. Chemical structure of curcumin (a) and synthesis of BDMC33 (b). 
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2. Results  
2.1. Inhibitory Action on NO Production via Down-Regulation of iNOS Expression  
The  induction  of  RAW  264.7  cells  into  an  inflammatory  state  by  combination  treatment  of  
IFN-γ/LPS  results  in  synthesis  and  secretion  of  NO.  In  Figure  2a,  BDMC33  shows  dose-related 
inhibition of NO production in which significant inhibition was still evident at 1.56  M (P < 0.05) and 
the IC50 was calculated at 13.66 ± 0.61  M. L-NAME, a standard NOS inhibitor, was used as positive 
drug control and significantly inhibited NO production (73.45 ± 1.94%) at 250  M. The question is 
whether the inhibition of NO secretion was due to the BDMC33 effect on intracellular targets or just 
the scavenging of secreted NO. Figure 2b shows that BDMC33 did not scavenge NO free radicals at 
all  concentrations  tested.  Then,  we  examined  whether  the  inhibitory  action  of  BDMC33  on  NO 
production was due to the suppression of iNOS activity or its expression. As demonstrated in Figure 2c, 
BDMC33 showed a slight reduction in nitrite synthesis at a concentration of 50 µM and had minimal 
inhibitory  effect  upon  iNOS  activity.  However,  western  blotting  analysis  demonstrated  BDMC33 
showed a significant dose-dependent, down-regulatory effect upon iNOS protein expression; doses as 
low as 10  M were significantly suppressive (P < 0.01). Dexamethasone, a potential anti-inflammatory 
steroid hormone, also significantly inhibited iNOS expression (43.88 ± 11.97%) at a concentration of  
10   M  (Figure  2d).  In  general,  these  results  indicated  that  the  inhibitory  action  of  BDMC33  on  
IFN-γ/LPS-induced NO production mainly results from the suppression of iNOS protein.  
2.2. Interference in Pro-Inflammatory Cytokine Production 
Tumor  necrosis  factor-α  and  IL-1β  are  pleiotropic  cytokines  that  have  been  implicated  as  key  
pro-inflammatory cytokines in immune and inflammatory response. Thus, we investigated the effects 
of BDMC33 on cytokine production and its gene expression by ELISA and semi-quantitative RT-PCR 
respectively. Figure 3a showed the effects of various treatments on TNF-α production and its gene 
expression  in  IFN-γ/LPS-induced  RAW  264.7  cells.  BDMC33  demonstrated  a  dose-dependent 
inhibitory  effect  upon  TNF-α  production  in  which  doses  as  low  as  6.25   M  were  significantly 
suppressive (P < 0.001) and the IC50 was calculated at 9.40 ± 1.67  M. Capsaicin was used as positive Int. J. Mol. Sci. 2012, 13                       
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drugs control and significantly inhibited the production of TNF-α (53.86 ± 2.77%). Semi-quantitative  
RT-PCR results revealed that IFN-γ/LPS treatment to RAW 264.7 cells caused the augmentation of 
TNF-α gene expression. In addition, BDMC33 displayed a dose-dependent inhibition in TNF-α gene 
expression as low as 12.5 µM (P < 0.05). Curcumin (30 µM) was used as positive control and showed 
slight inhibition (38.77 ± 2.01%) of TNF-α gene expression but to a lesser degree than BDMC33.  
Our  results  demonstrated  that  BDMC33  also  suppressed  IL-1β  synthesis  in  a  similar  trend  as 
observed for TNF-α synthesis. Figure 3b showed the effects of various treatments on protein and 
mRNA level of IL-1β in RAW 264.7 cells. BDMC33 inhibited IL-1β production in a dose-dependent 
manner  in  which  as  little  as  6.25   M  was  significantly  inhibited  (P  <  0.001)  and  the  IC50  was 
calculated at 29.66 ± 0.72  M. Quercetin was used as a positive drugs control and strongly inhibited 
the production of IL-1β (90.09 ± 2.88%). Furthermore, the gene expression of IL-1β was found to be 
significantly  inhibited  by  BDMC33  in  a  dose-dependent  manner.  PDTC  (50  µM)  was  used  as  a 
positive control and showed significant inhibition (43.69 ± 4.66%) of IL-1β gene expression but to a 
lesser degree than BDMC33.  
Figure  2.  Effects  of  BDMC33  on  NO  production,  NO  scavenging  activity  (cell-free 
system),  iNOS  activity  and  iNOS  expression  in  IFN-γ/LPS-induced  RAW  264.7 
macrophages. (a) Cells were stimulated for 17–20 h with 100 U/mL recombinant murine 
IFN-γ and 5  g/mL E. coli LPS and treated with increasing concentrations of BDMC33. 
The IC50 was calculated at 13.66 ± 0.61  M. Nitrite level was determined by the Griess 
reaction after treatment. L-NAME (250 µM) was used as standard iNOS inhibitor for NO 
inhibition; (b) Percentage of nitrite accumulation produced by sodium nitropruside (SNP) 
in the presence or absence of BDMC33 was determined by Griess assay. PTIO was used as 
positive control as a NO scavenger; (c) Cells were treated with IFN-γ/LPS for 12 h prior to 
treatment with increasing concentrations of BDMC33. L-NAME (250 µM) was used as a 
standard iNOS inhibitor for NO inhibition. Nitrite level was determined by Griess reaction 
after treatment; (d) Cells were stimulated for 20 h with combination of IFN-γ/LPS and 
treated with increasing concentrations of BDMC33. Whole cell lysates were assayed for 
iNOS expression by using Western blotting.  Immunoblotting of β-actin expression was 
used as loading control. Dexamethasone (DXM) was used as positive control for iNOS 
expression.  
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Figure 2. Cont. 
 
 
 
(c)  (d) 
The  expression  level  was  normalized  against  IFN-γ/LPS  treated  group.  C,  Basal  level  of 
nitrite/iNOS expression without IFN-γ/LPS treatment. All values are expressed in mean ± standard 
error of mean (S.E.M.) of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 
were significantly different from the IFN-γ/LPS-treated control group (second column). 
Figure  3.  (a)  Effect  of  BDMC33  on  TNF-α  production  and  gene  expression  in  
IFN-γ/LPS-induced RAW 264.7. The IC50 was calculated at 9.40 ± 1.67  M. Capsaisin  
(50 µM) and curcumin (30 µM) were used as positive drug control for protein and mRNA 
expression level of TNF-α respectively; (b) Effect of BDMC33 on IL-1β production and 
gene  expression  in  IFN-γ/LPS-induced  RAW  264.7.  The  IC50  was  calculated  at  
29.66 ± 0.72  M. Quercetin (2000 µM) and pyrroline dithiocarbamate (PDTC) (30 µM) 
were  used  as  positive  drug  control  for  protein  and  mRNA  expression  level  of  IL-1β 
respectively.  
   
 
(a) 
 
(b) 
C;  Basal  protein  and  mRNA  expression  level  of  TNF-α/IL-1β  without  IFN-γ/LPS  treatment.  
All  values  are  expressed  in  mean  ±  S.E.M.  of  three  independent  experiments.  *  P  <  0.05;  
*** P < 0.001, significantly different from IFN-γ/LPS-treated control group. Int. J. Mol. Sci. 2012, 13                       
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2.3. Attenuation of NF-κB and AP-1 DNA Binding Activity  
To further elucidate the underlying molecular mechanism mediated by BDMC33, the DNA binding 
activity of two important transcriptional factors (NF-κB and AP-1) involved in pro-inflammatory gene 
expression regulation were examined. Stimulation of LPS/IFN-γ resulted in a significant increase in 
DNA binding activity of both NF-κB and AP-1, as evaluated by electrophoretic mobility shift assay 
(EMSA). The specificity of binding was examined by competition with the unlabeled oligonucleotide 
(data not shown). We have demonstrated that the DNA binding activity of both NF-κB and AP-1 were 
significantly reduced in a nuclear extract obtained from IFN-γ/LPS-induced RAW 264.7 concomitant 
treated with different concentrations of BDMC33 (Figure 4). Curcumin was used as a positive control 
and  showed  significant  inhibition  in  DNA  binding  activity  of  AP-1  (63.54  ±  6.12%)  and  NF-κB  
(43.82 ± 0.74%). 
Figure  4.  Effect  of  BDMC33  on  DNA  binding  activity  of  transcriptional  factors  in  
IFN-γ/LPS-induced RAW 264.7 macrophages. Cells were stimulated with IFN-γ/LPS and 
treated  with  increasing  concentrations  of  BDMC33  for  2  h.  The  nuclear  protein  was 
extracted and tested for DNA binding of (a) AP-1 and (b) NF-κB by EMSA. Curcumin  
(30 µM) was used as positive drug control for DNA binding activity of both NF-κB and 
AP-1 transcriptional factors.  
   
(a) 
   
(b) 
The expression level was normalized against the IFN-γ/LPS treated group. C, Basal DNA binding 
activity  of  NF-κB  and  AP-1  without  IFN-γ/LPS  treatment.  The  results  are  expressed  in  
mean ± S.E.M. of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 are 
significantly different from the IFN-γ/LPS -treated control group (second column). Int. J. Mol. Sci. 2012, 13                       
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2.4. Effects of BDMC33 on NF-κB Activation 
To gain further insight into the mechanism of BDMC33-mediated regulation of NF-κB activation, 
we examined the inhibitory effects of BDMC33 on degradation and phosphorylation of I-κB as well as 
nuclear translocation of the NF-κB p65 subunit. In cells stimulated with IFN-γ/LPS, the expression 
level of the I-κB was down-regulated, concomitant with the increase of phosphorylated I-κB protein. 
However, the treatment of BDMC33 prominently sustained I-κB expression levels and inhibited the 
expression of phosphorylated I-κB protein in a concentration-dependent manner. PDTC, a standard  
NF-κB inhibitor, was used as positive drug control to maintain the I-κB protein level and showed 
strong inhibition in phosphorylated I-κB expression (Figure 5a). The IFN-γ/LPS-induced degradation 
of  I-κB can cause the release of NF-κB from the cytoplasmic NF-κB/I-κB complex and allow its 
translocation into the nucleus of cells. Therefore, we further investigate whether BDMC33 prevents the 
translocation of the p65 NF-κB into the nucleus after release from the I-κB. As shown in Figure 5b, the 
p65 subunit mainly localized on the cytoplasm region of the non-induced macrophages and stimulation 
of cells with IFN-γ/LPS resulting in p65 accumulation in cell nuclei. We have demonstrated that the 
treatment of BDMC33 (50 µM) abrogated the IFN-γ/LPS-induced p65 nuclear translocation. 
Figure 5. Effects of BDMC33 on I-κB degradation and I-κB phosphorylation as well as 
NF-κB  nuclear  translocation  in  IFN-γ/LPS  induced  RAW  264.7  macrophages.  (a)  Cell 
lysate  analyzed  by  western  blotting  using  anti-phospho-I-κB  and  anti-I-κB  antibodies. 
Expression  of  β-actin  expression  was  used  as  loading  control  and  normalized  against  
IFN-γ/LPS  treated  group;  (b)  Cells  cultured  in  chamber  slide  were  stimulated  with  
IFN-γ/LPS  and  treated  with  increasing  concentrations  of  BDMC33.  The  cellular 
localization of p65 NF-κB (fluorescein isothiocynate (FTIC) stained, green fluorescent) 
and  nucleus  region  (DRAQ5  stained,  red  fluorescent)  of  cells  were  identified  by 
immunofluorescence microscopy.  
 
   
(a) Int. J. Mol. Sci. 2012, 13                       
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Figure 5. Cont. 
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(b) 
All values are the mean ± S.E.M. of three independent experiments. * P < 0.05, ** P < 0.01,  
*** P < 0.001 are significantly different from IFN-γ/LPS-treated control group. 
2.5. Effects of BDMC33 on MAPKs Phosphorylation 
To  investigate  whether  the  ERK,  JNK  and  p38  MAPK  (mitogen-activated  protein  kinase)  are 
involved in suppression of inflammatory response by BDMC33, we next examined the activation of 
three subfamilies of MAPKs in detecting their phosphorylated forms by using Western blotting probed 
with specific anti-phosphokinase antibodies. The exposure of macrophages to IFN-γ/LPS resulted in a 
strong transient increase of phosphorylated ERK1/2, JNK1/2 and p38 levels at 30 min. As shown in 
Figure  6,  BDMC33  suppressed  IFN-γ/LPS–induced  activation  of  ERK1/2  and  JNK  1/2  in  a 
concentration-dependent  manner,  concomitantly,  the  amount  of  non-phosphorylated  ERK1/2  and 
JNK1/2 were unaffected either by  IFN-γ/LPS or BDMC33 treatment.  Although  BDMC33 showed 
minor  inhibition  of  p38  MAPK  phosphorylation,  but  the  change  was  not  statistically  significant. 
Standard positive drug controls (PD 98059, SP 600125 and SB 203580) were used and showed strong 
inhibition of the ERK1/2, JNK1/2 and p38 MAPK activation respectively. Int. J. Mol. Sci. 2012, 13                       
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Figure 6. Effects of BDMC33 on MAPKs activation in IFN-γ/LPS-induced RAW 264.7 
macrophages.  Cells  were  stimulated  with  IFN-γ/LPS  and  treated  with  increasing 
concentrations  of  BDMC33  for  30  min.  Whole  cell  lysates  were  analyzed  with  western 
blotting  with  specific  antibodies.  PD98059,  SP600125  and  SB203580  were  used  as  
standard inhibitors for (a) ERK, (b) JNK and (c) p38 activation, respectively. The ratio  
of  immunointensity  between  the  phospho-MAPKs  (p-ERK1/2,  p-JNK1/2  and  p-p38)  
and  total-MAPKs  (ERK1/2,  JNK1/2  and  p38)  were  calculated  from  three  
independent experiments.  
 
 
(a) 
 
 
(b) 
   
 
(c) 
Expression of β-actin expression was used as loading control and normalized against IFN-γ/LPS 
treated group. C; Basal level of MAPK expression without IFN-γ/LPS treatment. The results are 
expressed  in  mean  ±  S.E.M.  of  three  independent  experiments.  *  P  <  0.05,  **  P  <  0.01,  
*** P < 0.001, significantly different from IFN-γ/LPS-treated control group (second column). Int. J. Mol. Sci. 2012, 13                       
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2.7. Effects of BDMC33 on CD-14 and TLR-4 Expression  
The  level  of  accessory  molecule  expression  on  the  surface  of  macrophage  cells  reflects  their 
inflammatory responsiveness. To investigate whether BDMC33 modulates the accessory molecules on 
activated macrophages, the surface expression of TLR-4 and CD-14 of macrophages was analyzed by 
flow cytometer. As shown in Figure 7, the CD-14, constitutively expressed in a relatively high level 
and exposure of IFN-γ/LPS, caused the slight augmentation of CD-14 expression in RAW 264.7 cells, 
but  was  not  statistically  significant.  Conversely,  the  expression  of  TLR-4  was  relatively  low  and 
remained  unchanged  following  IFN-γ/LPS  treatment.  The  treatment  of  BDMC33  significantly 
inhibited the expression of CD-14 by approximately 32.30 ± 3.45% at the highest concentration tested 
(50 µM), while the TLR-4 expression was not altered by BDMC33 treatment. 
Figure  7. Effects of BDMC33 on  IFN-γ/LPS-treated surface expression of TLR-4 and  
CD-14  accessory  molecules  in  RAW  264.7  macrophages.  Cells  were  stimulated  with  
IFN-γ/LPS and treated with increasing concentrations of BDMC33 for 16 h. The cells were 
then collected and stained with FITC-conjugated anti-mouse CD-14 and PerCP-conjugated 
anti-mouse TLR-4 and acquired on FACSCalibur flow cytometer.  
 
 
The expression level was normalized against a IFN-γ/LPS-treated group. C; Basal level of CD-14 
or  TLR-4  without  IFN-γ/LPS  treatment.  The  results  are  expressed  in  mean  ±  S.E.M.  of  three 
independent experiments. * P < 0.05, significantly different from IFN-γ/LPS-treated control group 
(second column). 
2.8. Effects of BDMC33 on NO and TNF-α Production from Microglial BV-2 Cells 
We next addressed the question of whether the inhibitory action of BDMC33 on inflammatory 
mediator production was restricted to RAW 264.7 macrophages, so the experiments were repeated by 
replacement  of  the  RAW264.7  cells  with  BV-2  microgial  cells.  Stimulation  with  IFN-γ/LPS 
effectively augmented the NO (38.47 ± 1.08 µM) and TNF-α (7744.6 ± 193.47 pg/mL) production in Int. J. Mol. Sci. 2012, 13                       
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the  culture  medium  of  BV-2  microglial  cells  (Figure  8).  The  production  of  NO  and  TNF-α  from  
IFN-γ/LPS-induced microglial cells were found significantly suppressed by BDMC33, albeit in the 
low  level  as  compared  in  RAW  264.7  culture  system.  This  NO  inhibitory  action  was  not  due  to 
cytotoxicity by BDMC33 as assessed in MTT assay (Figure 9). 
Figure 8. Effects of BDMC33 on NO and TNF-α production in IFN-γ/LPS-induced BV-2 
microglia  cells.  Cells  were  stimulated  with  IFN-γ/LPS  and  treated  with  increasing 
concentrations  of  BDMC33.  Concentrations  of  NO2
−  and  TNF-α  in  the  media  was 
determined by Griess assay and ELISA, respectively.  
 
C, Basal level of NO2
−/TNF-α without IFN-γ/LPS treatment. All values are the mean ± S.E.M. of 
three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001, significantly different from 
IFN-γ/LPS-treated control group. 
Figure 9. Effects of BDMC33 on cell viability of RAW 264.7 and BV-2 cells. The cells 
were seeded into a 96-well plate were treated with increasing concentrations of BDMC33 
for 24 h and the cell viability determined by MTT assay.  
 
C, Basal level of cell viability without IFN-γ/LPS treatment. All values are mean ± S.E.M. of three 
different independent experiments. Int. J. Mol. Sci. 2012, 13                       
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3. Discussion 
It is well known that excessive production of NO is harmful. Pharmacological interference in the 
NO production cascade served as a promising chemotherapeutic strategy in anti-inflammatory agent 
development. In the present study, we have demonstrated a novel synthetic compound, BDMC33, 
which inhibited IFN-γ/LPS-induced NO production in RAW 264.7 macrophages in vitro. The NO 
inhibitory action of BDMC33 was neither mediated by its radical scavenging properties nor did it 
inhibit  iNOS  enzyme  activity,  but  rather  through  the  down-regulation  of  iNOS  expression.  The  
dose-dependent inhibition behavior of BDMC33 on NO production via iNOS expression showed that 
the  blockage  was  at  the  transcriptional  regulation  level  or  up-stream  signaling  molecule.  Several 
studies  have  also  reported  that  curcumin  and  its  derivatives  suppressed  iNOS  expression  in  
macrophages  via  interference  of  the  up-stream  signaling  pathways,  especially  on  NF-κB  and  
MAPK activation [26–28]. 
Interleukin-1β and TNF-α are pro-inflammatory cytokines that exert pleiotrophic effects on a variety 
of cells and play a crucial role in acute and chronic inflammatory as well as autoimmune disorders. 
Both cytokines have been implicated in the pathogenesis of the experimental joint inflammation model, 
whereby  administration  of  the  antagonizing  antibodies  are  effective  in  prevention  of  disease 
progression  and  joint  damage  [29,30].  Data  presented  herein  showed  that  BDMC33  treatment 
possessed a significant suppressive effect on TNF-α and IL-1β secretion in activated macrophages.  
The  RT-PCR  results  demonstrated  that  the  mRNA  expression  of  TNF-α  and  IL-1β  were  also  
dose-dependently  suppressed  by  BDMC33  treatment,  again  suggesting  interference  at  the 
transcriptional level of the cognate gene by BDMC33 treatment. Interestingly, Moon et al. (2010) have 
reported  that  curcumin  effectively  attenuated  arthritic  disease  progression  via  suppression  of  
TNF-α and IL-1β production in the collagen-induced arthritis (CIA) mouse model [31]; therefore, it is 
not surprising that BDMC33 might have an anti-arthritic effect in vivo.  
The regulation of inflammatory mediators is known to occur predominantly at the transcription 
level, whereby the transcriptional output is tightly controlled by a variety of transcriptional factors, 
including  NF-κB,  AP-1,  interferon  regulator  factor  1  (IRF-1),  CCAAT/enhancer-binding  protein  β 
(C/EBPβ) and cAMP response element binding (CREB) (Adcock & Caramori, 2001). Among these 
transcriptional factors, NF-κB and AP-1 are the key regulators for the transcription of iNOS, TNF-α 
and  IL-1β  [32–34].  The  EMSA  results  demonstrated  that  the  IFN-γ/LPS-induced  DNA  binding 
activities of AP-1 and NF-κB were markedly inhibited by BDMC33 in a dose-dependent manner. In 
addition, curcumin has been shown to inhibit transcriptional activity of NF-κB and AP-1 in primary 
microglial cells and human monocytes [35,36]. Based on these observations, we believed that the 
ability of BDMC33 to retain the basal biological activity of curcumin and its suppressive effect on 
inflammatory genes expression were mediated by the DNA binding activities of AP-1 and NF-κB. 
However,  we  cannot  exclude  the  inhibition  role  of  other  transcriptional  factors,  since  it  has  been 
proposed that IRF-1 and C/EBPβ are also essential factors in iNOS activation [37,38]. 
NF-κB is known to play  a  crucial role in inflammatory  gene regulation, whereby  activation of  
NF-κB results in phosphorylation, ubiquitinition and proteasome-mediated degradation of I-κB protein, 
followed  by  nuclear  translocation  and  DNA  binding  activity  of  NF-κB.  We  demonstrated  that 
BDMC33 treatment significantly interrupted NF-κB activation by preventing the degradation of I-κB Int. J. Mol. Sci. 2012, 13                       
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and  suppressed  the  formation  of  phosphorylated  I-κB,  thus  resulting  in  attenuation  of  p65  NF-κB 
nuclear translocation and affecting its DNA binding activity. These results suggested that BDMC33 
plays a possible role of inhibition on the up-stream protein of I-κB such as IKK or 26s proteosome. 
Previously, arsenite, cyclopentenone prostaglandin, s-nitrosothiol and anti-rheumatic gold compound 
have been reported to cause covalent modification of the IKKβ subunit by targeting a critical Cys
179 
residue, resulting in failure of NF-κB activation [39–42]. Interestingly, Conroy & Seto (1998) reported 
that  ketone  moiety  of  cyclohexanone-based  inhibitors  was  able  to  form  a  reversible  covalent 
hemithioketal bond with active site cysteine residue of papain, a cysteine protease [43]. Therefore, the 
ketone moiety present at the cyclohexanone skeleton of BDMC33 might be essential for the covalent 
modification of the IKKβ subunit via interaction with the Cys
179 residue, resulting in attenuation of 
NF-κB activation.  
MAPK  is  an  important  kinase-mediated  signaling  pathway  in  regulating  inflammatory  gene 
expression of cells in response to an extraordinarily diverse array of stimuli such as cytokine and 
endotoxin. In this study, we found that BDMC33 significantly inhibited the phosphorylation of ERK 
and JNK, but not p38 MAPK, in IFN-γ/LPS-induced macrophage. It was believed that the attenuation 
of  AP-1  DNA  binding  activities  by  BDMC33  was  mediated  via  the  suppression  of  ERK1/2  and 
JNK1/2 phosphorylation. MAPK/ERK kinase kinase (MEKK) 1–4, are the up-stream serine/threonine 
protein kinases of MAPKs which have been shown to cause strong stimulation of ERK and JNK 
activities, but inefficiently activate the p38 MAPK activity in human embryonic kidney cell (HEK 293) 
[44]. In addition, MEKK 2–3 stimulate the activation of NF-κB pathways through IKK-α and IKK-β 
activities in in vivo experiments [45]. Interestingly, Xue et al. (2005) reported that the electrophilic 
ketone moiety of the  cyclohexanone-based inhibitor suppressed proteolytic activity  of plasmin via 
interaction with the serine residue of the enzyme to give a reversibly formed hemiketal linkage [46]. 
Base on these observations, we suggested that the inactivation of JNK and ERK, as well as the NF-κB 
pathway by BDMC33, might result from the inhibition of the MEKKs’ activities by targeting the 
active site serine residue of the MEKKs. Furthermore, Palusiaka and Grabowski (2002) reported that 
the methoxy- group was a proton acceptor in hydrogen bonding. Thus, we believed that the methoxy- 
substitution group in the phenyl ring of BDMC33 was an excellent proton acceptor to form a hydrogen 
bond with the active site residue of the up-stream signaling molecules [47]. This was further supported 
by Pae et al. (2008) who suggested that the methoxy- group of the dimethoxycurcumin (a curcumin 
derivative)  was  a  significant  factor  in  inhibiting  NO  production,  iNOS  expression  and  NF-κB 
activation upon activated macrophages [48]. 
Accessory molecules such as TLR-4 and CD-14 play a critical role in LPS-mediated stimulation of 
macrophages  [6].  In  our  present  study,  BDMC33  was  shown  to  inhibit  the  surface  expression  of  
co-receptor  CD-14,  but  not  TLR-4.  Recently,  inhibition  of  CD-14  has  been  shown  effectively  to 
attenuate  early  inflammatory  response  in  the  animal  model  of  sepsis  [49].  In  addition,  IC14,  a 
recombinant  chimeric  monoclonal  antibody  recognizing  human  CD-14  has  shown  the  prominent 
suppressive effects on endotoxin-mediated inflammatory responses by antagonizing the inflammatory 
action of CD-14, and suppressed the TNF-α production in vivo and ex vivo [50,51]. Therefore, we 
postulated that the inhibition of the TNF-α and IL-1β production by BDMC33 were partly mediated by 
inhibition  of  the  CD-14  surface  expression,  and  subsequent  reduced  the  LPS  responsiveness  to 
macrophage activation.  Int. J. Mol. Sci. 2012, 13                       
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Microglial cells are macrophage-like cells that reside in the central nervous system and are crucial 
in the brain tissue defense system. However, persistent activation of microglial cells is believed to 
contribute  to  neurodegenerative  disease  such  as  Alzheimer’s  disease,  Parkinson’s  disease  and 
amyotrophic  lateral  sclerosis;  through  increasing  the  release  of  pro-inflammatory  mediators  or 
cytokines, including NO, TNF-α and ROS [52]. With an interest in determining possible cell-type 
specific effects of BDMC33, we showed that BDMC33 exhibits inhibitory activities on the production 
of NO and TNF-α in activated microglial cells, albeit at a low inhibition level. This indicates that the 
suppressive effects were not restricted to RAW 264.7 macrophages. Several studies have shown that 
LPS and glycosaminoglycan were less capable of activating the ERK signaling pathway in BV-2 cells, 
suggesting  that  insensitivity  of  ERK  activation  in  BV-2  cells  by  extracellular  stimulus  [53,54]. 
Therefore, it was speculated that the immunomodulatory  effect of  BDMC33, observed in the  BV-2 
cellular  system,  is  more  likely  to  act  strongly  on  the  ERK  signaling  pathway  due  to  the  low  
suppressive effect.  
4. Experimental  
4.1. Materials 
The  following  reagents  were  obtained  commercially:  Antibiotic  (5000  U/mL  penicillin  and  
5000  g/mL streptomycin), Dulbecco’s Modified Eagle’s Medium (DMEM) from Flowlab
TM (North 
Ride, Australia); Fetal bovine serum from iDNA Biotechnology Bte Ltd (Singapore); recombinant 
mouse  IFN-γ  from  eBioscience  Inc.  (San  Diego,  CA,  USA);  Escherichia  coli  (strain  055:B5);  
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl  tetratzolium  bromide  (MTT)  from  Fluka  Chemie  GmbH 
(Buchs,  Switzerland);  dimethyl  sulfoxide  (DMSO),  sulphanilamide,  naphthylenediamine,  
Nω-nitro-L-arginine-methyl ester hydrochloride (L-NAME), 2-phenyl-4,4,5,5-tetramethyllimidazoline- 
1-oxy-2-oxide (PTIO) from Sigma Chemical Co. (St. Louis, MO, USA). Rabbit polyclonal against 
mouse iNOS antibodies from Cayman Chemicals (Ann Arbor, M, USA). Rabbit polyclonal against 
human  p65,  ERK1/2,  pERK1/2,  p38,  pp38,  I-κB,  pI-κB,  HRP  conjugated  anti-β-actin,  fluorescein 
isothiocynate  (FIT-C)  conjugated  anti-mouse  TLR-4  and  Peridinin  chlorophyll  protein  complex 
(PerCP)  conjugated  anti-mouse  CD-14  from  Santa  Cruz  Biotechnology  (Santa  Cruz,  CA,  USA). 
Rabbit polyclonal against human JNK1/2, pJNK1/2 were purchased from Cell Signaling Inc. (Danvers, 
MA, USA). One-step RT-PCR kit and RNeasy Extraction kit were purchase from Qiagen (Valencia, 
CA, USA). The polyvinylidene fluoride (PVDF) membrane, HRP conjugated donkey anti-rabbit IgG 
and Enhanced Chemiluminescence Western Blotting Reagent (ECL) were purchased from Amersham 
Bioscience UK Ltd. (Buckinghamshire, UK). Nuc-Buster protein extraction kit from Novagen Inc. 
(Madison, WI, USA). LightShift Chemiluminescent EMSA Kit, Biodyne B positively charged nylon 
membrane and Biotin labeling kit from Pierce Biotechnology Inc. (Rockford, IL, USA). Gene and 
protein ladder from Fermentas (Glen Burnie, MD, USA). 
4.2. Synthesis of 2,6-Bis(2,5-dimethoxybenzylidene)Cyclohexanone (BDMC33) 
BDMC33  or  2,6-bis(2,5-dimethoxybenzylidene)cyclohexanone  was  chemically  synthesized  
(Figure 1b) at the Institute of Bioscience, Universiti Putra Malaysia as describe previously [25]. Int. J. Mol. Sci. 2012, 13                       
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4.3. Cell Culture 
The murine macrophage-like cell line (RAW 264.7) from European Collection of Cell Cultures 
(Porton Down, UK) and murine microglial cell line (BV-2), (a kind gift from Sharmili Vidyadaran, 
UPM),  were  both  maintained  in  DMEM  supplemented  with  10%  FBS,  4.5  g/L  glucose,  sodium 
pyruvate (1 mM), L-glutamine (2 mM), streptomycin (50  g/mL) and penicillin (50 U/mL) at 37 °C 
and  5%  CO2.  When  RAW  264.7  and  BV-2  cells  reached  confluency  of  80–90%,  the  cells  were  
scraped out and trypsinized, respectively followed by centrifugation at 110 xg at 4 °C for 10 min.  
The cell viability of cultured cells used in the assay was always >95%, as determined by trypan blue 
dye exclusion. 
4.4. Cell Viability  
The cytotoxicity of the BDMC33 on cultured cells was determined by assaying the reduction of 
MTT reagents to formazan salts. After treatment, the supernatant of 96-wells plate containing cells 
were removed and MTT reagents (0.05 mg/mL) were added into each well. The cells were incubated 
in 37 °C for 4 h and the formazan salts were dissolved by adding 100% DMSO. The absorbance was 
then  measured  at  570  nm  on  a  SpectraMax  Plus  Microplate  reader  (Molecular  Devices  Inc.,  
Sunnyvale, CA, USA). 
4.5. Measurement of Nitric Oxide Production 
RAW 264.7 or BV-2 cells (4 × 10
5 cells/well) were seeded into a tissue culture grade 96-well plate 
except for blank and incubated for 2 h at 37 °C, 5% CO2 for cell attachment. The attached cells were 
activated with 100 U/mL of recombinant IFN-γ and 5  g/mL of LPS with or without the presence of 
BDMC33 at a final volume 100  L/well. DMSO was used as vehicle to add BDMC33 to the culture 
medium and the final concentration of DMSO was 0.1% in all cultures. Cells were then incubated at  
37 °C, 5% CO2 for 17–20 h. The production of NO was determined by measuring the accumulation of 
nitrite, which was the stable metabolite of NO in culture medium by using Griess Assay. Briefly, an 
equal volume of Griess reagent (1% sulphanilamide and 0.1% N-(1-naphty)ethylenediamine in 2.5% 
H3PO4), mixed with culture supernatant  and color development, was quantified at 550 nm with a 
SpextraMax Plus microplate reader (Molecular Device). The amount of nitrite in the samples was 
calculated from a standard curve (0–100  M) of a freshly prepared sodium nitrite. 
4.6. Nitrite-Scavenging Activity 
Briefly, 50 µL of serially-diluted BDMC33 were added into a 96-well plate. Then, 50 µL of sodium 
nitroprusside (10 mM dissolved in PBS) solution was added into each well and incubated for 60 min 
with light exposure. The nitrite levels of the mixture were then determined by Griess assay as described 
in Section 2.5. Int. J. Mol. Sci. 2012, 13                       
 
 
3001
4.7. Indirect Determination of iNOS Activity 
RAW 264.7 cells (4 × 10
5 cells/well) were seeded into a tissue culture grade 96-well and triggered 
with IFN-γ/LPS for 12 h. Then, the cells were washed three times with phosphate buffer saline (PBS) 
and treated with increasing concentrations of BDMC33 for a further 12 h. The nitrite concentration of 
supernatant was determined by Griess assay as described in Section 2.5.  
4.8. Cytokine Immunoassay 
The cell culture supernatants were collected and analyzed for TNF-α and IL-1β secretion using 
commercial  ELISA  kits  (eBioscience,  USA).  The  protocols  provided  by  the  manufacturers  were 
followed to the detail. The data was acquired using a SpextraMax Plus microplate reader (Molecular 
Device). The concentration of TNF-α and IL-1β for each sample was calculated from their respective 
standard curves. 
4.9. Semi-Quantitative RT-PCR 
RAW 264.7 cells were triggered with IFN-γ/LPS as described earlier and treated with increasing 
concentrations of BDMC33 for 6 h. The total RNA from RAW 264.7 cells was extracted by using 
RNeasy Mini extraction kit (Qiagen, USA) and the primer sequences of the target genes were designed 
by  using  FastPCR  software  (Table  1).  The  extracted  RNAs  were  reverse-transcripted  into  cDNA, 
followed by an amplification step, by using one-step RT-PCR kit (Qiagen, USA). The extracted RNA 
was reverse-transcripted in the presence of specific primer for 30 min and PCR reactions were run for 
19–25 cycles of 94 °C (45 s), 63–64 °C (1 min) and 72 °C (45 s), using a thermal cycle (MJ Research, 
USA). Then, the 5  L of PCR products were electrophoresized by 1.8% agarose gel and visualized 
under  UV  after  ethidium  bromide  staining.  The  image  captured  using  VersaDoc  Imaging  Device 
(BioRad, USA) and relative volume of bands was measured by Quantity One software (BioRad, USA). 
Table 1. The primer sequences of the target genes.  
Target Gene  Gen Bank No.  Base Pair  Primer 
TNF-α  NM_013693  324 
Forward  5’-ACGGCATGGATCTCAAAGAC-3’ 
Reverse  5’-CGGACTCCGCAAAGTCTAAG-3’ 
IL-1β  NM_008361  497 
Forward  5’-TGACGTTCCCATTAGACAGC-3’ 
Reverse  5’-TGGGGAAGGCATTAGAAACA-3’ 
GADPH  M32599  269 
Forward  5’-TGTTCCTACCCCCAATGTGT-3’ 
Reverse  5’-CCCTGTTGCTGTAGCCGTAT-3’ 
4.10. Western Blotting Analysis 
RAW 264.7 cells were induced with combination of 100 U/mL IFN-γ and 5  g/mL LPS as described 
earlier and treated with different concentrations of BDMC33. To prepare the whole cell extract of 
RAW  264.7,  the  cells  were  scraped  out  of  the  culture  flask  and  rinsed  three  times  with  ice-cold  
Tris-sucrose washing buffer. Then, the cell pellets was resuspended in lysis buffer (0.5% Triton-X,  
2 mM EDTA, 2mM phenylmethylsulfonyl fluoride (PMSF), 2 ng/ L pepstatin A, 1 µg/mL leupeptin, Int. J. Mol. Sci. 2012, 13                       
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1 µg/mL apotinin, 10 mM Na3VO4, in Tris-HCl, pH 7.5) and incubated in ice for 30 min. Following 
incubation, the cells were sonicated at 20 Hz for 30 s. Then the cell was incubated for 20 min on ice 
and centrifuged at 25,150 x g at 4 °C for 30 min. The supernatants were collected and the protein 
content measured using a Bradford assay. In order to determine the expression of target protein, equal 
amounts of protein (10   g) were  electrophorized in a 10% SDS-PAGE and blotted onto a PVDF 
membrane (Amersham, UK). Membranes were blocked for 1 h at room temperature in a blocking 
buffer  (5%  non-fat  dry  milk,  0.081M  Na2HPO4,  0.015  M  NaHPO4,  0.15  M  NaCl,  pH  7.2,  0.1% 
Tween-20) and then incubated with primary antibodies for 1 h. The primary antibodies were used: 
rabbit  polyclonal  antibodies  against  iNOS  (1:2000),  ERK1/2  (1:2000),  pERK1/2  (1:1000),  p38 
(1:2000), pp38 (1:1000), JNK1/2 (1:2000), pJNK1/2 (1:1000), i-κB (1:2000), pi-κB (1:1000) and HRP 
conjugated  β-actin  (1:2500).  After  several  washes,  HRP-conjugated  donkey  anti-rabbit  IgG  
(1:1000–1:2000) were added and further incubated for 1 h. The proteins were detected by using ECL 
blotting  reagent  according  to  the  manufacturer’s  instruction.  The  image  captured  using  VersaDoc 
Imaging Device (BioRad, USA) and intensity of bands was measured by Quantity One software. 
4.11. Electrophoretic Mobility Shift Assay (EMSA) 
RAW  264.7  cells  were  induced  with  a  combination  of  100  U/mL  IFN-γ  and  5   g/mL  LPS  as 
described earlier and treated with different concentrations of BDMC33. The nuclear extracts were 
prepared  by  using  the  Nuc-Buster  protein  extraction  kit  (Novagen,  Inc.,  USA)  and  EMSA  or  
gel  shift  assay.  This  was  performed  using  a  LightShift  Chemiluminescent  EMSA  Kit  
(Pierce,  USA).  Consensus  sequence  of  NF-κB  (5’-AGTTGAGGGGACTTTCCCAGGC-3’  and  
5’-GCCTGGGAAAGTCCCCTCAACT-3’) and AP-1 (5’–CGCTTGATGACTCAGCCGGAA-3’ and 
5’-TTCCGGCTG AGTCATCAAGCG-3’) were used for electrophoretic mobility shift assay after end 
labeling of the oligonucleotide with biotin using the Biotin Labeling Kit (Pierce, USA). Briefly, 30 µg 
of  nuclear  protein  was  incubated  with  binding  buffer  (10  mM  Tris,  50  mM  KCl,  1  mM  DTT) 
supplement  with  50  mM  KCl  and  50  ng/µL  poly(dI.dC)  for  10  min  at  room  temperature  before 
incubation  with  50  fmol  of  labeled  oligonucleotide  for  another  20  min  at  room  temperature.  The 
specificity of protein binding to the DNA was confirmed by competition reactions, in which a 120-fold 
molar excess of unlabelled oligonucleotide was incubated with the extracts simultaneously before the 
addition  of  the  biotin-labeled  oligonucleotide.  DNA-protein  complexes  were  analyzed  by 
electrophoresis on 7% native polyacrylamide gel of TBE buffer (pH 8.5), followed by the transferring 
of DNA–protein complexes to a nylon membrane (Biodyne B Positively Charged Nylon Membrane). 
After transfer step, the membrane was immediately cross-linked at 120 mJ/cm
2 using a commercial 
UV-light  cross-link instrument (UV Stratalinker 1800) equipped  with 254 nm bulbs for 1 min. A 
chemiluminescent detection method using a luminol/enhanced solution and a stable peroxide solution 
was used as described by the manufacturer, and the membranes were exposed in VersaDoc Imaging 
Device (BioRad, USA). 
4.12. Fluorescence Microscopic Analysis of NF-κB Translocation 
NF-κB activation was assayed as translocation of the NF-κB subunit p65 from cytosol to nucleus. 
RAW  264.7  cells  were  cultured  on  glass  chamber  slides  and  stimulated  with  IFN-γ/LPS  with  or Int. J. Mol. Sci. 2012, 13                       
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without the presence of BDMC33. After treatment, the cells were washed with PBS, fixed with 0.2% 
glutaraldehyde plus 2% formaldehyde, permeabilized in 0.1% Triton X-100, and blocked in 2% bovine 
serum albumin for 1 h. Then, the cells were incubated with rabbit anti-p65 IgG (1:1000) for 1 h. After 
washing,  the  cells  were  incubated  with  FIT-C  conjugated  anti-rabbit  IgG  (1:1000)  plus  DRAQ5 
(1:1000) for nuclei staining for further 1 h, and mounted with anti-fading reagent (Merck, Germany). 
The image visualized using Axiolab fluorescence microscope (Zeiss, Germany).  
4.13. Flow Cytometry Analysis of TLR-4 and CD-14 
A fluorescent-activated cell sorting (FACS) analysis was performed to detect the accessory molecules 
on the RAW 264.7 cells. The cells were seeded into 6-well plate at a density of 5 × 10
4 cells, followed 
by  stimulation  and  BDMC33  treatment  as  describe  previously  for  20  h.  Cells  were  washed  with 
washing buffer (0.2% FBS in PBS) and stained with Fluorescein isothiocyanate (FIT-C) conjugated  
anti-mouse TLR-4 and Peridinin Chlorophyll Protein Complex (PerCP) conjugated anti-mouse CD-14 
at 4 °C for 30 min. The cells were washed twice by centrifugation in cold washing buffer at 350 g for 
10 min each and acquired on a FACSCalibur (BD Biosciences, USA).  
4.14. Statistical Analysis 
Statistical  analysis  was  performed  using  one–way  analysis  of  variance  (ANOVA)  followed  by 
Dunnett test post hoc for multi-group comparison test using GraphPad Prism software version 5.0. 
Statistical significance of differences between groups was accepted at P < 0.05. 
5. Conclusion 
In conclusion, we have demonstrated that BDMC33 effectively suppressed the production of NO, 
TNF-α and IL-1β upon IFN-γ/LPS induced macrophages. Moreover, the suppressive effects of the 
BDMC33 was associated with the down regulation of AP-1 DNA binding activity through blockade of 
the JNK and ERK signaling pathway; as well as inactivation of NF-κB signaling that resulted from the 
attenuation of the  I-κB  degradation,  I-κB phosphorylation,  NF-κB translocation and DNA binding 
activities, respectively (Figure 10). In addition, the suppressive effects of BDMC33 were partly mediated 
via reduction of CD-14 surface expression and not only restricted to the RAW 264.7 macrophages. 
Collectively,  the  experimental  data  suggests  that  the  anti-inflammatory  action  of  BDMC33  was 
attributed through interference in JNK-ERK-AP-1 and/or NF-κB signaling pathways in macrophages, 
which could be the possibility of its future pharmaceutical application in the control or management of 
inflammatory disorders.  
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Figure 10. A schematic diagram shows the mechanisms underlying the inhibitory action of 
BDMC33.  TLR-4  stimulation  by  LPS  activates  an  intracellular  signaling  cascade  that 
involves the recruitment of MyD88 (myeloid differentiation primary response gene-88) and 
results  in  the  phosphorylation  of  TRAF-6  (tumor-necrosis-factor-receptor-associated  
factor 6), subsequently activate NF-κB and MAPK pathways. The red blunt lines indicate 
the inhibition by BDMC33.  
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